Details of the Drug Formulations

General Information of Drug (ID: DM8X2EH)

• Drug Name: Everolimus Drug Info
• Synonyms: Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Advanced/metastatic breast cancer	2C60	Approved	[2]
Brainstem neoplasm		Approved	[1]
Breast carcinoma		Approved	[1]
Graft-versus-host disease	4B24	Approved	[1]
Intracranial meningioma		Approved	[1]
Leukemia		Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Mucosal melanoma		Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Prostate cancer	2C82.0	Approved	[1]
Renal cell carcinoma	2C90	Approved	[3]
Salivary gland squamous cell carcinoma		Approved	[1]
Tuberous sclerosis	LD2D.2	Approved	[1]
Kidney cancer	2C90.0	Phase 3	[3]
Castration-resistant prostate carcinoma		Investigative	[1]
Colon cancer	2B90.Z	Investigative	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[4]
Neuroblastoma	2D11.2	Investigative	[1]
Pancreatic acinar cell carcinoma		Investigative	[1]
Polycystic kidney disease	GB8Y	Investigative	[1]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[4]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6442177
  ChEBI ID: CHEBI:68478
  CAS Number: 159351-69-6
  TTD ID: D0K3QS
  VARIDT ID: DR00224
  INTEDE ID: DR0674
  ACDINA ID: D00260

Full List of Drug Formulations Containing This Drug

Everolimus 2 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07808	Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Mannitol; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses

Everolimus 3 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07810	Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Mannitol; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses

Everolimus 5 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07812	Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Mannitol; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses
Novartis Pharmaceuticals Corporation	F07811	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 0.25 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07804	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 0.5 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07805	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 0.75 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07806	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 10 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07807	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 2.5 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07809	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

Everolimus 7.5 mg tablet

Company	Formulation ID	FDA Description
Novartis Pharmaceuticals Corporation	F07813	Anhydrous lactose; Lactose monohydrate; Butylated hydroxytoluene; Magnesium stearate; Crospovidone; Hypromelloses

References

• [1] Everolimus FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
• [4] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.